|
 |
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials |
|
|
According to Phil Meeks, Azopharma Chief Executive Officer, “Xcelodose
technology allows us to more precisely prepare doses of clinical trial
material. This enables our clients to stretch out valuable research
material which is often costly and time consuming to make.” Mr. Meeks
continues, “Many of our clients are small or virtual companies who are
trying to minimize their financial burn rate. If we can save them a
trip to the synthesis lab or reduce their time in Preformulation, we’ve
gone a long way in stretching their resources.”
Xcelodose Technology Benefits:
•Ability to precisely fill low weights with minimal waste
eliminates need for blending and offers higher pharmaceutical quality
standards
•Minimizes or eliminates need for early formulation development and
associated reduction of stability testing ultimately increasing speed
of production over manual methods
•Reduces amount of API needed to get to first-in-human studies
•Reduces analytical development costs during early phase development
Mr. Meeks adds, “The introduction of Xcelodose to the production
methods offered by ApiCross Drug Delivery Technologies further broadens
our position as a global leader in the pharmaceutical development
industry.” Azopharma Product Development Group brings together the best
scientists in the field, state-of-the-art facilities and a focus on
quality that provides our client partners an unbeatable combination in
total product development.
Azopharma Product Development Group Includes:
• Azopharma Contract Pharmaceutical Services - Integrated
product development and CTM manufacturing for all dosage
forms.
• AniClin Preclinical Services - Preclinical services in support of early product development.
• AvivoClin Clinical Services - Human clinical pharmacology services for Phase I/II/III clinical trials.
• ApiCross Drug Delivery Technologies - Proprietary drug delivery platforms to solve difficult molecular challenges.
• Cyanta Analytical Laboratories - Analytical chemistry and inhalation services from development to quality control testing.
• ADMEquant Bioanalytical Services - Bioanalytical services supporting preclinical and clinical studies.
• IQsynthesis - Synthetic chemistry services from discovery to clinical API supplies including large scale API synthesis.
About Azopharma
Azopharma Product Development Group is FDA registered, DEA approved
and client audited on a regular basis. Azopharma’s mission is to help
our customers turn Ideas Into Cures™. In product development, it comes
down to the right people, their commitment and application of
experience. Partnering with Azopharma provides customers with the
confidence of assured success. We welcome visits to our facility in
Hollywood, FL as well as our other sites to conduct audits or meet with
our pharmaceutical scientists to outline a study that meets your
specific needs. Contact us at development@azopharma.com or 954-433-7480.
Contact Phil Meeks, CEO Azopharma Product Development Group 2 Oakwood
Boulevard, Suite 170 Hollywood, FL 33020 Phone: 954-433-7480
www.azopdogroup.co |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
|
